← Back to Clinical Trials
Recruiting NCT07404852

NCT07404852 Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07404852
Status Recruiting
Phase
Sponsor Washington University School of Medicine
Condition Large Vessel Occlusion
Study Type INTERVENTIONAL
Enrollment 65 participants
Start Date 2026-02-23
Primary Completion 2027-11-29

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
transcutaneous auricular vagal nerve stimulationSham transcutaneous vagal nerve stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 65 participants in total. It began in 2026-02-23 with a primary completion date of 2027-11-29.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory and brain injury laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.

Eligibility Criteria

Inclusion Criteria: * Adult patients who present with acute ischemic strokes due to large vessel occlusions Exclusion Criteria: * \<18 years old * patients with presumed chronic large vessel occlusions * NIHSS\<6 * pre-morbid modified Rankin score (mRS) \>2 * unable to initiate treatment under 24 hours from symptom discovery * Chronic or acute infection, Recent surgery, active immune disease * life expectancy \<3 months * patients' undergoing active cancer or immunosuppressive/modulating therapy * patients with sustained bradycardia on arrival with a heart rate \<50 beats per minute.

Contact & Investigator

Central Contact

Angela Birke, MS

✉ birkea@wustl.edu

📞 (314) 362-5291

Frequently Asked Questions

Who can join the NCT07404852 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Large Vessel Occlusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07404852 currently recruiting?

Yes, NCT07404852 is actively recruiting participants. Contact the research team at birkea@wustl.edu for enrollment information.

Where is the NCT07404852 trial being conducted?

This trial is being conducted at St Louis, United States.

Who is sponsoring the NCT07404852 clinical trial?

NCT07404852 is sponsored by Washington University School of Medicine. The trial plans to enroll 65 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology